Company Filing History:
Years Active: 2010-2013
Title: Eyal Klopfer: Innovator in Isoquinolinium Compounds
Introduction
Eyal Klopfer, based in Tel Aviv, Israel, is a prominent inventor known for his contributions in the field of medicinal chemistry. With a total of four patents to his name, Klopfer has made significant advancements, particularly in relation to isoquinolinium compounds and their applications in pharmaceuticals.
Latest Patents
One of his most recent patents, titled "Isoquinolinium compounds useful in the preparation of cisatracurium and associated intermediates," focuses on novel isoquinolinium compounds. This invention outlines methods for producing these compounds and converting them into cisatracurium, particularly cisatracurium besylate. The isoquinolinium compounds described can be purified easily, allowing for the production of pure cisatracurium besylate without the need for sophisticated techniques like HPLC purification. Another pivotal patent, "Process for producing cisatracurium compounds and associated intermediates," elaborates on processes for synthesizing isoquinolinium compounds and transforming them into various cisatracurium salts, further underscoring Klopfer’s expertise in this specialized area.
Career Highlights
Eyal Klopfer is associated with Chemagis Ltd., a company dedicated to developing innovative chemical solutions. His work there has positioned him as a key figure in pharmaceutical development, especially in the creation of compounds that can lead to significant medical breakthroughs.
Collaborations
Throughout his career, Klopfer has collaborated with notable individuals such as Vladimir Naddaka and Shady Saeed. These partnerships have strengthened his research efforts and contributed to the advancements reflected in his patent portfolio.
Conclusion
Eyal Klopfer stands out as a dedicated inventor in the field of medicinal chemistry. His innovative patents, particularly around isoquinolinium compounds and their uses, contribute significantly to the pharmaceutical realm. As a key member of Chemagis Ltd., Klopfer continues to push the boundaries of research and development, paving the way for future medical therapies.